{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:55:58Z","timestamp":1761540958448},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T00:00:00Z","timestamp":1260835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Congenital factor XIII (FXIII) deficiency is an extremely rare, yet potentially life\u2010threatening, bleeding disorder, with a 30% rate of spontaneous intracranial haemorrhage. Routine prophylactic management is recommended for all individuals with clinically relevant (FXIII) deficiency and for all symptomatic individuals with congenital factor deficiency. Fibrogammin<jats:sup>\u00ae<\/jats:sup> P is a purified, pasteurized concentrate of FXIII that appears to carry negligible risk of viral transmission, unlike other unprocessed products containing FXIII. An ongoing Phase II\/III study of Fibrogammin<jats:sup>\u00ae<\/jats:sup> P in patients with congenital FXIII deficiency is being conducted to evaluate the prophylactic efficacy and long\u2010term safety of this product. Using retrospective chart review data from subjects enrolled in the Phase II\/III study, the current analysis was designed to compare spontaneous bleed\u2010event rates prior to and after the initiation of Fibrogammin<jats:sup>\u00ae<\/jats:sup> P prophylaxis. Seven subjects were evaluable for comparison, having received no other prophylactic FXIII\u2010containing product during the 24\u2003months prior to study entry. The mean annual number of spontaneous bleeds was 2.5\u2003events per year prior to Fibrogammin<jats:sup>\u00ae<\/jats:sup> P prophylaxis and 0.2\u2003events per year during Fibrogammin<jats:sup>\u00ae<\/jats:sup> P prophylaxis (<jats:italic>P<\/jats:italic>\u2003=\u20030.01). Patients reported no severe bleeds during Fibrogammin<jats:sup>\u00ae<\/jats:sup> P therapy. This small sample supports a consistent and clinically meaningful reduction in spontaneous bleeding with prophylactic use of Fibrogammin<jats:sup>\u00ae<\/jats:sup> P.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02123.x","type":"journal-article","created":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T02:42:21Z","timestamp":1260931341000},"page":"316-321","source":"Crossref","is-referenced-by-count":48,"title":["Prophylactic therapy with Fibrogammin<sup>\u00ae<\/sup> P is associated with a decreased incidence of bleeding episodes: a retrospective study"],"prefix":"10.1111","volume":"16","author":[{"given":"J.","family":"LUSHER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. W.","family":"PIPE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"ALEXANDER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"NUGENT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.2.e32"},{"key":"e_1_2_7_3_2","first-page":"1354","article-title":"The therapy of factor 13 deficiency","volume":"23","author":"Duckert F","year":"1965","journal-title":"Bibl Haematol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1654918"},{"key":"e_1_2_7_5_2","first-page":"145","article-title":"Plasma thromboplastin antecedent and the activation of factor IX","volume":"4","author":"Duckert F","year":"1960","journal-title":"Thromb Diath Haemorrh"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1160\/TH05-06-0388","article-title":"Characterisation of six novel A\u2010subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder","volume":"95","author":"Schroeder V","year":"2006","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00944.x"},{"key":"e_1_2_7_8_2","first-page":"14","article-title":"Clinical aspects of congenital coagulation Factor XIII deficiency","volume":"5","author":"Gootenberg JE","year":"1992","journal-title":"Biomed Prog"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-01-0034"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-999040"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02577.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.02.009"},{"key":"e_1_2_7_13_2","article-title":"Safety and efficacy of Fibrogammin\u00ae P for the treatment of patients with severe FXIII deficiency","volume":"1","author":"Dreyfus M","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602960501100416"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0788"},{"key":"e_1_2_7_16_2","article-title":"Clinical course and management of 7 patients with congenital factor XIII deficiency. Experience of a single institution","volume":"3","author":"Garcia\u2010Talavera J","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02123.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02123.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:37:27Z","timestamp":1698683847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02123.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,25]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02123.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02123.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,25]]}}}